Analgesic properties of fluproquazone.
Fluproquazone, a new analgesic, was compared to a dextropropoxyphene hydrochloride and paracetamol combination (Cosalgesic) in a single blind trial lasting for five days. The trial included cases of various soft-tissue lesions and osteoarthrosis. Treatment was given to 170 patients, 84 of whom received fluproquazone and 86 the combination analgesic. The patients themselves made daily records of the severity of pain on a 100 mm visual analogue scale and in both treatment groups there was highly significant relief of pain, but with no significant differences between them. However, the incidence of side-effects was significantly higher with dextropropoxyphene hydrochloride-paracetamol (30%) than with fluproquazone (9%).
D000082:Acetaminophen / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D011431:Dextropropoxyphene / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D052999:Quinazolinones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D011799:Quinazolines; D052999:Quinazolinones; D000082:Acetaminophen; D011431:Dextropropoxyphene; C023491:fluproquazone